The Changing Landscape and Advances in the Treatment of Multiple Myeloma (APAC) | Bloomberg Professional Services
Webinar

The Changing Landscape and Advances in the Treatment of Multiple Myeloma (APAC)

We will outline the overview of the current treatments available for multiple myeloma including the loss of market exclusivity for key products in the space. We will also discuss the latest research and innovations that are driving new treatments to help improve patient outcomes in multiple myeloma, including the debate over the risk of secondary malignancies from cell therapy.

Speakers

Aude Gerspacher

Global Head of Healthcare

Bloomberg Intelligence

Aude Gerspacher is the Global Head of Healthcare Research at Bloomberg Intelligence. Prior to her current role, Ms. Gerspacher was the U.S. Director of Research for the regional equities team. She specializes in litigation and patent disputes in pharmaceuticals and biotechnology. Previously, Ms. Gerspacher worked as a Senior Corporate Counsel at Pfizer. Before transitioning in-house, Ms. Gerspacher worked as a patent attorney at Cozen O'Connor, a large full service law firm and Cooper & Dunham, a patent boutique firm in New York City. Ms. Gerspacher is a licensed patent attorney barred in the state of New York. She holds a bachelor of science in microbiology, a master of science in molecular biology and genetics, and a JD from Case Western University.

Sam Fazeli

Head of EMEA Research

Bloomberg

Sam Fazeli is a senior analyst and the EMEA head of Bloomberg Intelligence, a dynamic platform for in-depth research available on the Bloomberg Professional service at BI . Dr. Fazeli specializes in global pharmaceuticals, bringing over 20 years of experience conducting equity research as a pharmaceutical analyst, working at firms such as Nomura International and HSBC. Prior to joining Bloomberg in 2010, Dr. Fazeli worked at Piper Jaffray, Ltd. as a pharmaceutical analyst and head of European research. Before transitioning to investment banking, he was a research scientist for seven years. Dr. Fazeli has been ranked a top analyst by both the U.K. and Pan-European Extel surveys. He received a bachelor’s of science from Cardiff University, and a Ph.D. in pharmacology from the University of London.

View the latest upcoming and on-demand Bloomberg webinars.
Learn more